Antidotes to Toxins and Drugs
From Natural Sources to Drug Discovery in Toxicology
- 1st Edition - November 24, 2023
- Editors: Mihnea-Alexandru Găman, Chukwuebuka Egbuna
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 4 7 2 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 9 9 6 - 7
Antidotes to Toxins and Drugs: From Natural Sources to Drug Discovery in Toxicology presents recent advances in the discovery of natural antidotes to toxins, drug intoxi… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote- Details recent advances in the discovery of natural antidotes from medicinal plants and phytochemicals
- Includes advances in the discovery of antidotes to drug intoxications and overdoses
- Describes modern screening assays for toxins and drug intoxications
- Features information on recent advances in toxicology
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Chapter 1. Antidotes to drug intoxications or drug overdoses
- Abstract
- Introduction
- Analgesia
- Anesthetics
- Psychotropic drugs
- Antipsychotics
- Clonidine
- Antiepileptics
- Cardiovascular medications
- Anticoagulants
- Insulin
- Methotrexate
- Antihistamines
- Alcohol
- Illicit substances
- Future projections
- Conclusion
- References
- Chapter 2. Antidotes to insect toxins, bee venom; wasp and hornet venoms
- Abstract
- List of abbreviations
- Introduction
- Conclusion
- References
- Chapter 3. Antidotes to reptile toxins chemical composition of snake venoms; toxic effects of snake venom
- Abstract
- Introduction
- Chemical composition of snake venoms
- Toxic effects of snake venom
- Ethnomedicinal uses of plants as an antidote against snake venom
- Antidotes from natural sources against snake venom
- Future projections
- Conclusion
- References
- Chapter 4. Antidotes to mycotoxins and mushroom toxins
- Abstract
- Introduction
- Most toxic mycotoxins
- Why pinpoint accumulation of mycotoxin is dangerous?
- Preexposure control
- What are toxins and antidotes
- Special mycotoxicosis
- Antidotes for ergotism
- Mushroom mycotoxins
- Genetic modification to prevent mycotoxicosis
- Degradation of mycotoxins by enzymes – can antidotes be developed?
- Role of nanotechnology in the development of mycotoxin antidotes
- Treatment of mycotoxin with cold plasma
- Conclusion
- Future perspectives
- References
- Chapter 5. Antidotes to nonreptile animal toxins
- Abstract
- Antidotes to poisonous frogs and toads
- Toxins from frogs and toads and their toxic effects
- Steroids: bufogenines and bufotoxins
- Alkaloids
- Other toxins
- Antidotes to frog/toad poisoning
- Propranolol hydrochloride
- Activated charcoal
- Digoxin-specific Fab fragments (Digibind)
- Conclusion
- References
- Chapter 6. Antidotes to toxic substances from the marine world
- Abstract
- Introduction
- Toxicity and toxin composition
- Conclusion
- References
- Chapter 7. Antidotes to aflatoxicosis in humans
- Abstract
- Introduction
- Biological disturbance from AFs
- Conclusion
- References
- Chapter 8. Drug-induced liver injury: toxins and antidotes
- Abstract
- Introduction
- Epidemiology and importance of DILI
- Mechanism/pathogenesis and types of DILI
- Diagnosis of DILI
- Causality assessment
- New biomarkers
- Risk factors for drug-induced liver injury
- Types of agents associated with DILI with general or specific management
- Analgesics
- Diclofenac
- References
- Further reading
- Chapter 9. Natural toxins and drug discovery opportunities
- Abstract
- List of abbreviations
- Introduction
- Historical perspective: natural toxins as drugs
- Natural toxins with potential for drug development
- Natural toxins as candidate drugs under clinical trial
- Challenges
- Conclusion
- References
- Chapter 10. Antidotes to toxins and drugs in the European Union: public health, policy, and regulatory framework
- Abstract
- Introduction
- Relevant terms and definitions
- Antidotes across times and contexts
- Regulatory authorities and professional bodies
- EU health policy for antidotes to drugs and toxins
- References
- Chapter 11. Benefits and safety of probiotics in gastrointestinal diseases
- Abstract
- Introduction
- Mechanisms through which probiotics positively impact health
- Helicobacter pylori infection
- Irritable bowel syndrome
- Inflammatory bowel diseases
- Crohn’s disease
- QOL: quality of life, pro—probiotics, pl—placebo
- Ulcerative colitis
- Pouchitis
- Safety of probiotics
- Conclusion and future perspectives
- References
- Chapter 12. Clozapine—serious adverse effects and clinical management
- Abstract
- Introduction
- Chemical and pharmacological proprieties of clozapine
- Indications of clozapine and patient treatment eligibility
- Initiation, monitoring, and discontinuation of clozapine treatment
- Adverse effects and management
- Conclusions and future projections
- References
- Chapter 13. Iatrogenic opioid and hypnotics withdrawal syndromes in adults in intensive care
- Abstract
- Neurobiology of addiction and withdrawal
- Pharmacokinetic and pharmacodynamic aspects in critically-ill patients with importance for IWS
- Epidemiology and issues regarding iatrogenic withdrawal syndromes in adult ICU patients
- Risk factors for developing IWS in adult critically-ill patients
- IWS diagnosis
- Preventive strategies and treatment of opioid and hypnotic IWS
- Treatment of IWS
- Conclusions
- References
- Chapter 14. Laboratory evaluation of intoxications: toxins and drugs
- Abstract
- Introduction
- Laboratory testing in drug intoxications
- Common analytical methods used in clinical laboratories for drug intoxications
- Chromatography
- Other toxic compound identification methods
- Laboratory evaluation of common drug intoxications
- Methods used in bacterial toxin intoxications
- Laboratory testing for common toxin detection
- Other toxins
- Future projections
- Conclusion
- References
- Chapter 15. Antidodes in esthetic medicine
- Abstract
- Introduction
- Dermal fillers—a short history, classification
- Antidotes to BT injections—indirect antagonists of BT
- Conclusions
- References
- Index
- No. of pages: 420
- Language: English
- Edition: 1
- Published: November 24, 2023
- Imprint: Elsevier
- Paperback ISBN: 9780128244722
- eBook ISBN: 9780323859967
MG
Mihnea-Alexandru Găman
Mihnea-Alexandru Găman received his MD at the Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. Dr. Găman is currently specializing in clinical hematology at the Department of Hematology, Centre of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania. He has published more than 100 papers in international impact factor journals, as well as served as editor and author for international and national books/book chapters. In addition, Dr. Găman also serves as Scientific Editor, Associate Editor, Editorial Board Member and Peer-Reviewer for several international and national journals. His main fields of interest include hematology, molecular biology, oncology, internal medicine, medical education, fundamental sciences, and translational/interdisciplinary medicine.
CE
Chukwuebuka Egbuna
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.